Brief: Fulcrum Therapeutics Enters Into A Collaboration And License Agreement With Sanofi

Fulcrum Therapeutics

13/05/2024 12:26

May 13 (Reuters) - Fulcrum Therapeutics Inc  FULC.O :
    * FULCRUM THERAPEUTICS ENTERS INTO A COLLABORATION AND
LICENSE
AGREEMENT WITH SANOFI FOR THE DEVELOPMENT AND COMMERCIALIZATION
OF LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    * FULCRUM WILL RECEIVE AN UPFRONT PAYMENT OF $80.0 MILLION,
AND IS
ELIGIBLE TO RECEIVE $975.0 MILLION IN POTENTIAL MILESTONES
    * FULCRUM EXPECTS TO REPORT TOPLINE DATA FROM REACH, GLOBAL
PHASE
3 CLINICAL TRIAL, IN Q4 OF 2024
    * FULCRUM AND SANOFI WILL EQUALLY SHARE FUTURE GLOBAL
DEVELOPMENT
COSTS

Source text for Eikon:  ID:nGNX23f1R1 
Further company coverage:  FULC.O 

 ((Reuters.Briefs@thomsonreuters.com;))